Wave makes $100M pub­lic of­fer­ing af­ter dos­ing first sub­jects with GSK-part­nered RNA edit­ing drug

Wave Life Sci­ences is of­fer­ing $100 mil­lion in shares just short­ly af­ter it start­ed test­ing its first RNA edit­ing can­di­date in healthy sub­jects, which trig­gered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER